The meta-analysis also demonstrated that overweight/obesity was significantly associated with a poor response to neoadjuvant anti-HER2 therapy (OR = 0.68; P = 0.007). This evidence concerns the gene ERBB2 and obesity due to melanocortin 4 receptor deficiency.